NewAmsterdam Pharma (NASDAQ:NAMSW – Get Free Report)’s stock price rose 3.5% during trading on Wednesday . The company traded as high as $19.38 and last traded at $19.38. 241 shares traded hands during mid-day trading, a decline of 86% from the average daily volume of 1,777 shares. The stock had previously closed at $18.72.
NewAmsterdam Pharma Trading Up 3.5%
The firm’s 50-day moving average price is $22.22 and its 200-day moving average price is $22.05.
Institutional Trading of NewAmsterdam Pharma
A hedge fund recently bought a new stake in NewAmsterdam Pharma stock. Aristeia Capital L.L.C. purchased a new position in NewAmsterdam Pharma (NASDAQ:NAMSW – Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 15,708 shares of the company’s stock, valued at approximately $397,000.
About NewAmsterdam Pharma
NewAmsterdam Pharma, Inc is a clinical-stage biotechnology company focused on the development of orally delivered peptide therapeutics for the treatment of metabolic diseases. Drawing upon proprietary peptide chemistry and formulation technologies, the company aims to transform injectable treatments for conditions such as type 2 diabetes, obesity and related cardiometabolic disorders into convenient, once-daily oral medications. By harnessing advances in peptide stabilization and targeted delivery, NewAmsterdam Pharma seeks to improve patient adherence and expand access to novel therapies.
The company’s lead program is an oral glucagon‐like peptide‐1 (GLP-1) receptor agonist currently in early clinical trials.
Recommended Stories
- Five stocks we like better than NewAmsterdam Pharma
- Could Truth API Become Trump Media’s First Meaningful Revenue Driver?
- Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying
- Moog Is More Than a Missile Maker, and Wall Street Is Noticing
- A Boring Dividend Growth Strategy Becomes a Solid Defensive Play
Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
